Galmed Pharmaceuticals Ltd. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Galmed Pharmaceuticals Ltd. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q2 2024.
  • Galmed Pharmaceuticals Ltd. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$1.12M, a 29.8% increase year-over-year.
  • Galmed Pharmaceuticals Ltd. annual Net Income (Loss) Attributable to Parent for 2023 was -$6.91M, a 61.3% increase from 2022.
  • Galmed Pharmaceuticals Ltd. annual Net Income (Loss) Attributable to Parent for 2022 was -$17.9M, a 45% increase from 2021.
  • Galmed Pharmaceuticals Ltd. annual Net Income (Loss) Attributable to Parent for 2021 was -$32.5M, a 12.8% decline from 2020.
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$1.12M +$474K +29.8% Apr 1, 2024 Jun 30, 2024 6-K 2024-08-28
Q1 2024 -$1.28M +$555K +30.3% Jan 1, 2024 Mar 31, 2024 6-K 2024-08-28
Q2 2023 -$1.59M +$2.14M +57.3% Apr 1, 2023 Jun 30, 2023 6-K 2024-08-28
Q1 2023 -$1.83M +$4.31M +70.2% Jan 1, 2023 Mar 31, 2023 6-K 2024-08-28
Q2 2022 -$3.73M +$4.66M +55.5% Apr 1, 2022 Jun 30, 2022 6-K 2023-08-09
Q1 2022 -$6.14M +$2.76M +31% Jan 1, 2022 Mar 31, 2022 6-K 2023-08-09
Q2 2021 -$8.4M -$2.87M -51.9% Apr 1, 2021 Jun 30, 2021 6-K 2022-08-04
Q1 2021 -$8.91M -$2.84M -46.9% Jan 1, 2021 Mar 31, 2021 6-K 2022-08-04
Q2 2020 -$5.53M Apr 1, 2020 Jun 30, 2020 6-K 2021-08-05
Q1 2020 -$6.06M Jan 1, 2020 Mar 31, 2020 6-K 2021-08-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.